Randy Schekman, a professor of molecular and cell biology at UC Berkeley and winner of the 2013 Nobel Prize in physiology or medicine, spoke at the Aging, Research and Technology Innovation Summit on Sept. 17. He spoke about Parkinson’s disease, including a new collaborative research initiative he is leading calledAligning Science Across Parkinson’s (ASAP).
The U.S. Patent and Trademark Office (USPTO) granted the University of California (UC) and its partners, the University of Vienna and Emmanuelle Charpentier, a new CRISPR-Cas9 patent, bringing the team’s continually expanding patent portfolio to 15. In the coming months, based on applications allowed by the USPTO, UC’s CRISPR-Cas9 patent portfolio will increase to 18. Together, these patents cover compositions and methods for CRISPR-Cas9 gene-editing, including targeting and editing genes and modulating transcription in any setting, such as within plant, animal and human cells.
A $20 million gift will support research at UC Berkeley and UCSF into dyslexia and similar neurodevelopmental language-processing disorders as part of the new UCSF-UC Berkeley Schwab Dyslexia and Cognitive Diversity Center. The joint program will draw on research in neuroscience, cognitive psychology, education and public health, among other disciplines. At UC Berkeley, it will be headquartered in Berkeley Way West, the building that houses the UC Berkeley Department of Psychology, School of Public Health, and Graduate School of Education.
Transfer student Novene Cusseaux, from Vallejo, California, plans to study genetics and plant biology. “With genetics, there are a lot of things that haven’t been discovered yet. I just want to find out something new that we didn’t know existed... Now it should be my time to show my kids that you can do it at any age. You need to practice what you preach.”
The U.S. Patent and Trademark Office (USPTO) has awarded a new patent to the University of California (UC), University of Vienna, and Dr. Emmanuelle Charpentier covering methods of producing a genetically modified cell through the introduction of the Cas9 protein, or a nucleic acid encoding the Cas9 protein, as well as a single molecule DNA-targeting RNA. This patent (U.S. 10,351,878) covers the use of this method in a cell.